Form 4: Catalyst Pharma CCO Reports Equity Compensation Grants

Catalyst Pharmaceuticals' Chief Commercial Officer, Jeffrey Del Carmen, reported the acquisition of new stock options and restricted stock units, alongside the vesting and tax-related disposition of existing units.

Summary

• Jeffrey Del Carmen, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc. (CPRX), reported transactions involving the company's common stock and derivative securities.
• On November 21, 2025, 5,603 shares of common stock were acquired due to the vesting of restricted stock units.
• Concurrently, 1,641 shares of common stock were disposed of on November 21, 2025, to satisfy applicable withholding taxes upon the vesting of restricted common stock.
• Following these transactions, Mr. Del Carmen directly beneficially owns 3,962 shares of common stock.
• On November 20, 2025, Mr. Del Carmen was granted 106,873 options to purchase common stock with an exercise price of $22.77 per share, expiring on November 20, 2032.
• These options will vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• Also on November 20, 2025, Mr. Del Carmen was granted 32,257 Restricted Stock Units (RSUs), which will vest in three equal tranches on November 20, 2026, November 20, 2027, and November 20, 2028.
• An additional 5,603 Restricted Stock Units were reported as converted on November 21, 2025, with the first tranche of shares delivered on that date. These RSUs vest in equal tranches on November 21, 2025, November 21, 2026, and November 21, 2027.

Sentiment

Score: 7

Explanation: This filing reports routine equity compensation grants and vesting events for a key executive, which is generally positive as it aligns management's incentives with shareholder interests. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The grant of 106,873 stock options and 32,257 Restricted Stock Units to the Chief Commercial Officer aligns management's long-term interests with shareholder value creation.
• The vesting of existing Restricted Stock Units indicates the successful achievement of prior compensation milestones.

Negatives

• The disposition of 1,641 shares for tax withholding is a routine event associated with equity compensation vesting and is not indicative of negative sentiment or performance.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The equity grants align the Chief Commercial Officer's financial interests with the long-term performance of the company, potentially motivating decisions that enhance shareholder value.

Next Steps

• Future tranches of stock options and restricted stock units will vest on November 20, 2026, November 20, 2027, and November 20, 2028.
• The remaining tranches of the 5,603 Restricted Stock Units will vest on November 21, 2026, and November 21, 2027.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Jeffrey Del Carmen, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Chief Commercial Officer